Clinical Study
Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial
Table 3
Plasmatic and erythrocyte membrane PUFA concentrations after HTT and PT.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
All parameters were evaluated before and after HTT. All results were expressed as mean ± standard deviation (SD) (number of replicates = 3). PT: placebo treatment; HTT: 15 mg/day hydroxytyrosol treatment; AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid. |